Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Sunilkumar Kakadia, Naveen Yarlagadda, Ramez Awad, Madappa Kundranda, Jiaxin Niu, Boris Naraev, Lida Mina, Tomislav Dragovich, Mark Gimbel & Fade Mahmoud. (2018) Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets and Therapy 11, pages 7095-7107.
Read now
Read now
Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard Scolyer, Ji-Ying Song, Inge Verbrugge, Christoph Hoeller, Reinhard Dummer, John B. A. G. Haanen, Georgina V. Long & Christian U. Blank. (2016) Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology 5:12.
Read now
Read now
Blanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, Siwen Hu-Lieskovan & Antoni Ribas. (2016) Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. OncoImmunology 5:7.
Read now
Read now
Shannon M. Steinberg & Mary Jo Turk. (2015) BRAF-inhibition and tumor immune suppression. OncoImmunology 4:2.
Read now
Read now
Laura J Vella, Miles C Andrews, Andreas Behren, Jonathan Cebon & Katherine Woods. (2014) Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment. Expert Review of Clinical Immunology 10:8, pages 1107-1123.
Read now
Read now
Alfonso Zambon, Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, Richard Marais & Caroline J Springer. (2013) BRAF as a therapeutic target: a patent review (2006 – 2012). Expert Opinion on Therapeutic Patents 23:2, pages 155-164.
Read now
Read now
Articles from other publishers (52)
Maximilian Haist, Henner Stege, Michael Kuske, Julia Bauer, Annika Klumpp, Stephan Grabbe & Matthias Bros. (2023) Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews 42:2, pages 481-505.
Crossref
Crossref
Jihoon Kim, Paul A. Archer, Margaret P. Manspeaker, Alexa R.C. Avecilla, Brian P. Pollack & Susan N. Thomas. (2023) Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma. Journal of Controlled Release 357, pages 655-668.
Crossref
Crossref
Peter Lawrence Smith, Katarzyna Piadel & Angus George Dalgleish. (2021) Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy. Vaccines 9:12, pages 1392.
Crossref
Crossref
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran & Hussein A. Tawbi. (2021) Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery 11:6, pages 1368-1397.
Crossref
Crossref
Minyi Chen, Franziska Werner, Christine Wagner, Martin Simon, Erika Richtig, Kirsten D. Mertz, Johannes Griss & Stephan N. Wagner. (2021) Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Rishi Suresh, Arturas Ziemys & Ashley M. Holder. (2020) Dissecting the Lymphatic System to Predict Melanoma Metastasis. Frontiers in Oncology 10.
Crossref
Crossref
Weiyi Peng, Leila J. Williams, Chunyu Xu, Brenda Melendez, Jodi A. McKenzie, Yuan Chen, Heather L. Jackson, Kui S. Voo, Rina M. Mbofung, Sara Elizabeth Leahey, Jian Wang, Gregory Lizee, Hussein A. Tawbi, Michael A. Davies, Axel Hoos, James Smothers, Roopa Srinivasan, Elaine M. Paul, Niranjan Yanamandra & Patrick Hwu. (2019) Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma. Clinical Cancer Research 25:21, pages 6406-6416.
Crossref
Crossref
Johannes Griss, Wolfgang Bauer, Christine Wagner, Martin Simon, Minyi Chen, Katharina Grabmeier-Pfistershammer, Margarita Maurer-Granofszky, Florian Roka, Thomas Penz, Christoph Bock, Gao Zhang, Meenhard Herlyn, Katharina Glatz, Heinz Läubli, Kirsten D. Mertz, Peter Petzelbauer, Thomas Wiesner, Markus Hartl, Winfried F. Pickl, Rajasekharan Somasundaram, Peter Steinberger & Stephan N. Wagner. (2019) B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications 10:1.
Crossref
Crossref
Marcella Occelli, Anna M. Vandone, Carolina Cauchi & Marco C. Merlano. (2019) Melanoma. Anti-Cancer Drugs 30:6, pages 543-553.
Crossref
Crossref
F. Toia, A. B. Di Stefano, S. Meraviglia, E. Lo Presti, R. Pirrello, G. Rinaldi, F. Fulfaro, F. Dieli & A. Cordova. (2019)
Γ
δ
T Cell-Based Immunotherapy in Melanoma: State of the Art
. Journal of Oncology 2019, pages 1-8.
Crossref
Crossref
Vito Longo, Oronzo Brunetti, Amalia Azzariti, Domenico Galetta, Patrizia Nardulli, Francesco Leonetti & Nicola Silvestris. (2019) Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers 11:4, pages 539.
Crossref
Crossref
Ismael Navas-Delgado, José García-Nieto, Esteban López-Camacho, Maciej Rybinski, Rocio Lavado, Miguel Ángel Berciano Guerrero & José F. Aldana-Montes. (2019) VIGLA-M: visual gene expression data analytics. BMC Bioinformatics 20:S4.
Crossref
Crossref
Kamran Abri & Adil I. Daud. 2019. Melanoma. Melanoma
687
697
.
Tamer B. Shabaneh, Aleksey K. Molodtsov, Shannon M. Steinberg, Peisheng Zhang, Gretel M. Torres, Gadisti A. Mohamed, Andrea Boni, Tyler J. Curiel, Christina V. Angeles & Mary Jo Turk. (2018) Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis. Cancer Research 78:17, pages 5038-5049.
Crossref
Crossref
Hong Cai, Eun-Ae Cho, Yue Li, Jim Sockler, Christopher R. Parish, Beng H. Chong, Jarem Edwards, Tristan J. Dodds, Peter M. Ferguson, James S. Wilmott, Richard A. Scolyer, Gary M. Halliday & Levon M. Khachigian. (2018) Melanoma protective antitumor immunity activated by catalytic DNA. Oncogene 37:37, pages 5115-5126.
Crossref
Crossref
J. D. Nosanchuk, A. Jeyakumar, A. Ray, E. Revskaya, Z. Jiang, R. A. Bryan, K. J. H. Allen, R. Jiao, M. E. Malo, B. L. Gómez, A. Morgenstern, F. Bruchertseifer, D. Rickles, G. B. Thornton, A. Bowen, A. Casadevall & E. Dadachova. (2018) Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. Scientific Reports 8:1.
Crossref
Crossref
Kamran Abri & Adil I. Daud. 2017. Melanoma. Melanoma
1
11
.
Davide Bedognetti, Jessica Roelands, Julie Decock, Ena Wang & Wouter Hendrickx. (2017) The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences 1:5, pages 429-445.
Crossref
Crossref
R. Reinhard, C. Gebhardt, A. Schmieder, V. Umansky & J. Utikal. (2017)
Recurrent tattoo reactions in a patient treated with
BRAF
and
MEK
inhibitors
. Journal of the European Academy of Dermatology and Venereology 31:8.
Crossref
Crossref
Rolando Ruiz, Sohail Jahid, Melissa Harris, Diego M. Marzese, Francisco Espitia, Priya Vasudeva, Chi-Fen Chen, Sebastien de Feraudy, Jie Wu, Daniel L. Gillen, Tatiana B. Krasieva, Bruce J. Tromberg, William J. Pavan, Dave S. Hoon & Anand K. Ganesan. (2017) The RhoJ-BAD signaling network: An Achilles’ heel for BRAF mutant melanomas. PLOS Genetics 13:7, pages e1006913.
Crossref
Crossref
Alexandra Frazao, Marina Colombo, Emmanuelle Fourmentraux-Neves, Meriem Messaoudene, Sylvie Rusakiewicz, Laurence Zitvogel, Eric Vivier, Frédéric Vély, Florence Faure, Brigitte Dréno, Houssem Benlalam, Fanny Bouquet, Ariel Savina, Eric Pasmant, Antoine Toubert, Marie-Françoise Avril & Anne Caignard. (2017)
Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on
BRAF
V600E Melanoma Lines with Vemurafenib
. Cancer Immunology Research 5:7, pages 582-593.
Crossref
Crossref
Meriem Messaoudene, Alexandra Frazao, Pierre Jean Gavlovsky, Antoine Toubert, Nicolas Dulphy & Anne Caignard. (2017) Patient?s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Frontiers in Immunology 8.
Crossref
Crossref
Shannon M. Steinberg, Tamer B. Shabaneh, Peisheng Zhang, Viktor Martyanov, Zhenghui Li, Brian T. Malik, Tamara A. Wood, Andrea Boni, Aleksey Molodtsov, Christina V. Angeles, Tyler J. Curiel, Michael L. Whitfield & Mary Jo Turk. (2017) Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Research 77:7, pages 1599-1610.
Crossref
Crossref
David J. Hermel & Patrick A. Ott. (2017) Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer and Metastasis Reviews 36:1, pages 43-50.
Crossref
Crossref
Daniele Viarisio, Karin Müller-Decker, Jessica C. Hassel, Jean-Claude Alvarez, Christa Flechtenmacher, Michael Pawlita, Lutz Gissmann & Massimo Tommasino. (2017) The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice. Journal of Investigative Dermatology 137:1, pages 261-264.
Crossref
Crossref
Marcel Deken, Ji-Ying Song, Jules Gadiot, Adriaan Bins, Paula Kroon, Inge Verbrugge & Christian Blank. (2016) Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. International Journal of Molecular Sciences 17:12, pages 2149.
Crossref
Crossref
Tomonori Yaguchi & Yutaka Kawakami. (2016) Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. International Immunology 28:8, pages 393-399.
Crossref
Crossref
Sangeetha M. Reddy, Alexandre Reuben & Jennifer A. Wargo. (2016) Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Current Oncology Reports 18:7.
Crossref
Crossref
Paula Kroon, Jules Gadiot, Marlies Peeters, Alessia Gasparini, Marcel A. Deken, Hideo Yagita, Marcel Verheij, Jannie Borst, Christian U. Blank & Inge Verbrugge. (2016) Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. Cancer Immunology, Immunotherapy 65:6, pages 753-763.
Crossref
Crossref
Yoshihiro Hayakawa, Manabu Kawada, Hiroyoshi Nishikawa, Takahiro Ochiya, Hideyuki Saya, Hiroyuki Seimiya, Ryoji Yao, Masahiro Hayashi, Chieko Kai, Akira Matsuda, Tomoki Naoe, Atsushi Ohtsu, Taku Okazaki, Hideo Saji, Masataka Sata, Haruhiko Sugimura, Yuichi Sugiyama, Masakazu Toi & Tatsuro Irimura. (2016) Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs. Cancer Science 107:2, pages 189-202.
Crossref
Crossref
Shin Foong Ngiow, Sherene Loi, David Thomas & Mark J. Smyth. 2016. Tumor Immunology. Tumor Immunology
1
24
.
Jonathan M. Pitt, Dalil Hannani, Marie Vétizou & Laurence Zitvogel. 2016. Encyclopedia of Immunobiology. Encyclopedia of Immunobiology
569
580
.
Chantale Bernatchez, Zachary A. Cooper, Jennifer A. Wargo, Patrick Hwu & Gregory Lizée. 2016. Melanoma. Melanoma
371
416
.
Jennifer A. Wargo, Alexandre Reuben, Zachary A. Cooper, Kevin S. Oh & Ryan J. Sullivan. (2015) Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Seminars in Oncology 42:4, pages 601-616.
Crossref
Crossref
Siwen Hu-LieskovanStephen MokBlanca Homet MorenoJennifer TsoiLidia RobertLucas GoedertElaine M. PinheiroRichard C. KoyaThomas G. GraeberBegoña Comin-AnduixAntoni Ribas. (2015)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in
BRAF
V600E
melanoma
. Science Translational Medicine 7:279.
Crossref
Crossref
Jennifer A. Wargo, Zachary A. Cooper & Keith T. Flaherty. (2014) Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. Cancer Discovery 4:12, pages 1377-1386.
Crossref
Crossref
Kristina M. Ilieva, Isabel Correa, Debra H. Josephs, Panagiotis Karagiannis, Isioma U. Egbuniwe, Michiala J. Cafferkey, James F. Spicer, Mark Harries, Frank O. Nestle, Katie E. Lacy & Sophia N. Karagiannis. (2014)
Effects of
BRAF
Mutations and
BRAF
Inhibition on Immune Responses to Melanoma
. Molecular Cancer Therapeutics 13:12, pages 2769-2783.
Crossref
Crossref
Shannon M. Steinberg, Peisheng Zhang, Brian T. Malik, Andrea Boni, Tamer B. Shabaneh, Katelyn T. Byrne, David W. Mullins, Constance E. Brinckerhoff, Marc S. Ernstoff, Marcus W. Bosenberg & Mary Jo Turk. (2014) BRAF Inhibition Alleviates Immune Suppression in Murine Autochthonous Melanoma. Cancer Immunology Research 2:11, pages 1044-1050.
Crossref
Crossref
Siwen Hu-LieskovanLidia RobertBlanca Homet MorenoAntoni Ribas. (2014)
Combining Targeted Therapy With Immunotherapy in
BRAF
-Mutant Melanoma: Promise and Challenges
. Journal of Clinical Oncology 32:21, pages 2248-2254.
Crossref
Crossref
Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, Dennie T. Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, F. Stephen Hodi, Gordon J. Freeman, Marcus W. Bosenberg, Martin McMahon, Keith T. Flaherty, David E. Fisher, Arlene H. Sharpe & Jennifer A. Wargo. (2014) Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. Cancer Immunology Research 2:7, pages 643-654.
Crossref
Crossref
Ping-Chih Ho, Katrina M. Meeth, Yao-Chen Tsui, Bhaskar Srivastava, Marcus W. Bosenberg & Susan M. Kaech. (2014) Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ. Cancer Research 74:12, pages 3205-3217.
Crossref
Crossref
Miles C Andrews, Katherine Woods, Jonathan Cebon & Andreas Behren. (2014) Evolving role of tumor antigens for future melanoma therapies. Future Oncology 10:8, pages 1457-1468.
Crossref
Crossref
Michelle T. Ashworth & Adil I. Daud. (2014) Combinatorial Approach to Treatment of Melanoma. Hematology/Oncology Clinics of North America 28:3, pages 601-612.
Crossref
Crossref
Molly H. Jenkins, Shannon M. Steinberg, Matthew P. Alexander, Jan L. Fisher, Marc S. Ernstoff, Mary Jo Turk, David W. Mullins & Constance E. Brinckerhoff. (2014)
Multiple murine BRaf
V600E
melanoma cell lines with sensitivity to PLX4032
. Pigment Cell & Melanoma Research 27:3, pages 495-501.
Crossref
Crossref
Emma Shtivelman, Michael A. Davies, Patrick Hwu, James Yang, Michal Lotem, Moshe Oren, Keith T. Flaherty & David E. Fisher. (2014) Pathways and therapeutic targets in melanoma. Oncotarget 5:7, pages 1701-1752.
Crossref
Crossref
Margaret K. Callahan, Gregg Masters, Christine A. Pratilas, Charlotte Ariyan, Jessica Katz, Shigehisa Kitano, Valerie Russell, Ruth Ann Gordon, Shachi Vyas, Jianda Yuan, Ashok Gupta, Jon M. Wigginton, Neal Rosen, Taha Merghoub, Maria Jure-Kunkel & Jedd D. Wolchok. (2014) Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. Cancer Immunology Research 2:1, pages 70-79.
Crossref
Crossref
Blanca Homet & Antoni Ribas. (2014) New drug targets in metastatic melanoma. The Journal of Pathology 232:2, pages 134-141.
Crossref
Crossref
Mei Li M. Kwong, Bart Neyns & James C. Yang. (2013) Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy. Clinical Cancer Research 19:19, pages 5292-5299.
Crossref
Crossref
Antoni Ribas & Jedd D Wolchok. (2013) Combining cancer immunotherapy and targeted therapy. Current Opinion in Immunology 25:2, pages 291-296.
Crossref
Crossref
Paolo A. Ascierto, Michael Kalos, David A. Schaer, Margaret K. Callahan & Jedd D. Wolchok. (2013) Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clinical Cancer Research 19:5, pages 1009-1020.
Crossref
Crossref
Dennie T. Frederick, Adriano Piris, Alexandria P. Cogdill, Zachary A. Cooper, Cecilia Lezcano, Cristina R. Ferrone, Devarati Mitra, Andrea Boni, Lindsay P. Newton, Chengwen Liu, Weiyi Peng, Ryan J. Sullivan, Donald P. Lawrence, F. Stephen Hodi, Willem W. Overwijk, Gregory Lizée, George F. Murphy, Patrick Hwu, Keith T. Flaherty, David E. Fisher & Jennifer A. Wargo. (2013) BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research 19:5, pages 1225-1231.
Crossref
Crossref
Peter Hersey, Stuart Gallagher & Branka Mijatov. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer
143
155
.